Kanishk Kumar: TFPI Market Size – Advancing Hemostasis and Antithrombotic Therapy
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, posted on LinkedIn:
”Tissue Factor Pathway Inhibitors (TFPI) Market: Advancing Hemostasis and Antithrombotic Therapy
Tissue Factor Pathway Inhibitors (TFPIs) are emerging as a novel class of anticoagulants, offering targeted approaches to manage thrombotic disorders with potentially improved safety profiles compared to conventional therapies. As cardiovascular and thrombotic disease burdens rise globally, TFPI-based therapies are gaining attention for their role in precision medicine. Despite challenges like clinical development complexity and regulatory pathways, the TFPI market shows strong potential for innovation.
DelveInsight’s report – TFPI Market Size, Target Population, Competitive Landscape and Market Forecast – 2034 – provides:
– Comprehensive epidemiological analysis across major markets
– Current and emerging therapeutic strategies, including recombinant proteins, monoclonal antibodies, and fusion molecules
– Pipeline landscape with novel candidates and ongoing clinical trials
– Market dynamics – key drivers, barriers, and opportunities shaping TFPI adoption
– Competitive landscape highlighting leading pharmaceutical and biotechnology innovators
Key Players in the TFPI Companies space include Bayer, Novo Nordisk, Sanofi, Pfizer, Bristol Myers Squibb, CSL , Shire, Alnylam Pharmaceuticals, and others.
With ongoing R&D, growing patient populations, and global initiatives to improve thrombotic care, the TFPI market is poised for significant growth and innovation through 2034.
Access the full report here.”
Stay updated with Hemostasis Today.
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
-
Apr 6, 2026, 16:38Linda Vorberg: A Detailed Analysis on The Usefulness of CT for DL-Based Stroke Lesion Segmentation
-
Apr 6, 2026, 16:37Colleen Hearn: Telestroke Helps Resource-Limited Facilities Gain Access to Unavailable Expertise
-
Apr 6, 2026, 16:37Nicolas Hubacz: AI Maps Neuroplasticity in Stroke Recovery – How the Brain Adapts After Injury
-
Apr 6, 2026, 16:36Cristina de Diego Alonso: Movement Is Not Just an Exercise, It Is The Rhythm of Daily Life
-
Apr 6, 2026, 16:35Charles Okyere Boadu: What Is The Most Likely Cause of Persistent Thrombocytopenia Despite Transfusion?
-
Apr 6, 2026, 16:34Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
-
Apr 6, 2026, 16:31Wolfgang Miesbach: New Real-World Data Reveal Ongoing Burden in Moderate-to-Severe Haemophilia A
-
Apr 6, 2026, 16:26Heghine Khachatryan։ Targeting High Risk Antiphospholipid Syndrome in Pregnancy with Hydroxychloroquine